Results 21 to 30 of about 146,874 (392)

Glutamine metabolic microenvironment drives M2 macrophage polarization to mediate trastuzumab resistance in HER2‐positive gastric cancer

Cancer Communications, 2023
Trastuzumab is a first‐line targeted therapy for human epidermal growth factor receptor‐2 (HER2)‐positive gastric cancer. However, the inevitable occurrence of acquired trastuzumab resistance limits the drug benefit, and there is currently no effective ...
Xingbin Hu, Zhenfeng Ma, Beibei Xu, Shulong Li, Z. Yao, B. Liang, Jiao Wang, W. Liao, Li Lin, Chunlin Wang, S. Zheng, Qijing Wu, Qiong Huang, Le Yu, Fenghua Wang, Min Shi   +15 more
semanticscholar   +1 more source

Exosomal Linc00969 induces trastuzumab resistance in breast cancer by increasing HER-2 protein expression and mRNA stability by binding to HUR

Breast Cancer Research, 2023
Background Breast cancer (BC) is the most common malignant disease in female patients worldwide. In HER-2+ BC patients, trastuzumab therapy is associated with a better prognosis.
Cuiwei Liu, Chong Lu, Lamu Yixi, Jiaxing Hong, Fang Dong, Shengnan Ruan, Ting Hu, Xiangwang Zhao   +7 more
doaj   +1 more source

Trastuzumab-induced upregulation of a protein set in extracellular vesicles emitted by ErbB2-positive breast cancer cells correlates with their trastuzumab sensitivity

Breast Cancer Research, 2020
Background ErbB2/HER2 oncoprotein often drives breast cancers (BCs) which are treated with the anti-ErbB2 antibody trastuzumab. The efficacy of trastuzumab-based metastatic BC therapies is routinely assessed by imaging studies.
Arik Durcker, Byong Hoon Yoo, Iman Aftab Khan, Dongsic Choi, Laura Montermini, Xiaoyang Liu, Sanja Jovanovic, Tallal Younis, Kirill V. Rosen   +8 more
doaj   +1 more source

First-line treatment of patients with HER2-positive metastatic gastric and gastroesophageal junction cancer

Biomolecules & Biomedicine, 2022
Fluoropyrimidine+cisplatin/oxaliplatin+trastuzumab therapy is recommended for the first-line treatment of HER2-positive metastatic gastric adenocarcinoma.
Selin Aktürk Esen, Yakup Ergun, Cihan Erol, Rukiye Arikan, Muhammed Muhiddin Er, Muhammed Mustafa Atci, Atakan Topçu, Gökhan Uçar, Baran Akagündüz, Musa Bariş Aykan, Miraç Özen, Naziyet Köse Baytemur, Melike Özçelik, Elif Şahin , Denizcan Güven , Serkan Menekşe, Naziye Ak, Fatih Teker, Engin Kut, Teoman Şakalar, Özkan Alan, Turgut Kaçan , Nazim Serdar Turhal, Saadettin Kiliçkap, Sema Türker , Mehmet Ali Nahit Şendur, Osman Köstek, Mustafa Karaağaç , Abdullah Sakin , Haci Mehmet Türk, Dilek Çağlayan , Şener Cihan, Yusuf Açikgöz , Doğan Uncu   +33 more
doaj   +1 more source

Tucatinib vs Placebo, Both in Combination With Trastuzumab and Capecitabine, for Previously Treated ERBB2 (HER2)-Positive Metastatic Breast Cancer in Patients With Brain Metastases

JAMA Oncology, 2022
Key Points Question Can tucatinib, trastuzumab, and capecitabine provide systemic and intracranial benefit for patients with ERBB2 (HER2)-positive metastatic breast cancer and brain metastases?
N. Lin, R. Murthy, V. Abramson, C. Anders, T. Bachelot, P. Bedard, V. Borges, D. Cameron, L. Carey, A. J. Chien, G. Curigliano, M. DiGiovanna, K. Gelmon, G. Hortobagyi, S. Hurvitz, I. Krop, S. Loi, S. Loibl, V. Mueller, Mafalda Oliveira, E. Paplomata, M. Pegram, D. Slamon, A. Zelnak, J. Ramos, W. Feng, Eric P. Winer   +26 more
semanticscholar   +1 more source

A novel HER2-targeting antibody 5G9 identified by large-scale trastuzumab-based screening exhibits potent synergistic antitumor activity

EBioMedicine, 2020
Background: Pertuzumab is currently used in combination with trastuzumab as the first-line treatment for HER2-positive metastatic breast cancer. However, pertuzumab was originally developed independently from trastuzumab and was later incidentally found ...
Xiaoyu Ding, Wanjian Gu, Yujie Zhong, Xiaoyao Hao, Jinyu Liu, Shukai Xia, Lan Luo, Mingjiu Chen, Chunni Zhang   +8 more
doaj   +1 more source

Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer

JAMA Oncology, 2021
This phase 3 randomized clinical trial compares the clinical efficacy of margetuximab vs trastuzumab, each with chemotherapy, in patients with pretreated ERBB2-positive advanced breast cancer.
H. Rugo, S. Im, F. Cardoso, J. Cortés, G. Curigliano, A. Musolino, M. Pegram, G. Wright, C. Saura, S. Escrivá-de-Romaní, M. De Laurentiis, C. Lévy, U. Brown-Glaberman, J. Ferrero, M. de Boer, Sung-Bae Kim, K. Petráková, D. Yardley, O. Freedman, E. Jakobsen, B. Kaufman, R. Yerushalmi, P. Fasching, J. Nordstrom, E. Bonvini, S. Koenig, Sutton Edlich, Shengyan Hong, E. Rock, W. Gradishar   +29 more
semanticscholar   +1 more source

[225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts

EJNMMI Radiopharmacy and Chemistry, 2023
Background Trastuzumab (Herceptin) has improved the outcome for patients with HER2-positive breast cancer (BC) but brain metastases (BM) remain a challenge due to poor uptake of trastuzumab into the brain.
Misaki Kondo, Zhongli Cai, Conrad Chan, Nubaira Forkan, Raymond M. Reilly   +4 more
doaj   +1 more source

Combination of 131I-trastuzumab and lanatoside C enhanced therapeutic efficacy in HER2 positive tumor model

Scientific Reports, 2021
Lanatoside C has a promising anti-tumor activity and is a potential candidate for radiosensitizers. In this study, we have investigated the therapeutic efficacy of the combination of 131I-trastuzumab and lanatoside C for inhibition of human epidermal ...
Nagarajan Vinod, Jae Hyung Kim, Seungbum Choi, Ilhan Lim   +3 more
doaj   +1 more source

Prolonged survival of patients receiving trastuzumab beyond disease progression for HER2 overexpressing metastatic breast cancer (MBC) [PDF]

, 2005
Background: The aim of this retrospective analysis was to evaluate the impact of trastuzumab-based regimens on the survival of patients with HER2-overexpressing metastatic breast cancer (MBC).
Baselga J, Baselga J, Cobleigh MA, Gelmon KA, Kaplan EL, Marty M, Robert NJ, Slamon D, Tripathy D, Vogel CL   +9 more
core   +1 more source